Ribose (Furanose)

Ribose (Furanose)

SCHEMBL378844

Clc1nc2c(Cl)cccc2[nH]1.OC[C@H]1OC(O)[C@H](O)[C@@H]1O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.45
▸ GMNN O75496 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ PMP22 Q01453 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ STAT6 P42226 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ HPGD P15428 1/20 0.41
▸ PSMB8 P28062 1/20 0.40
▸ MAOB P27338 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ SLC5A2 P31639 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL17477040 1.00 KDM4E (0.45) KDM4EGMNNLMNAMAPTBLM
SCHEMBL66295 0.77 PSMB8 (0.59) KDM4ELMNAMAPTSMN1; SMN2NFKB1
SCHEMBL8853010 0.74 KDM4E (0.51) KDM4EGMNNLMNAMAPTBLM
SCHEMBL6008963 0.72 KDM4E (0.55) KDM4EGMNNLMNAMAPTBLM
SCHEMBL8367682 0.72 KDM4E (0.55) KDM4EGMNNLMNAMAPTBLM
SCHEMBL8371823 0.72 KDM4E (0.55) KDM4EGMNNLMNAMAPTBLM
B-D-Galactose SCHEMBL9493917 0.72 ALDH1A1 (0.48) SLC5A2
B-D-Galactose SCHEMBL27938149 0.71 SLC5A2 (0.47) SLC5A2
B-D-Galactose SCHEMBL27864238 0.69 KDM4E (0.44) KDM4ESLC5A2
Ribose (Furanose) SCHEMBL5139187 0.69 PYGL (0.47) SLC5A2PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016019096-A1 INHIBITION OF HSV-1-ASSOCIATED CORNEAL NEOVASCULARIZATION USING INHIBITORS OF CYCLIN-DEPENDENT KINASE 9 XAVIER UNIVERSITY OF LOUISIANA (US) 2016-02-04 — — WO claimed
WO-2016019096-A1 INHIBITION OF HSV-1-ASSOCIATED CORNEAL NEOVASCULARIZATION USING INHIBITORS OF CYCLIN-DEPENDENT KINASE 9 XAVIER UNIVERSITY OF LOUISIANA (US) 2016-02-04 — — WO disclosed
US-20150359854-A1 INSULIN RECEPTOR INDUCED ELASTIN PRODUCTION THE HOSPITAL FOR SICK CHILDREN (CA) 2015-12-17 — — US disclosed
US-9006170-B2 Compositions for elastogenesis and connective tissue treatment HUMAN MATRIX SCIENCES, LLC (US) 2015-04-14 — — US disclosed
US-20130184199-A1 INSULIN RECEPTOR INDUCED ELASTIN PRODUCTION THE HOSPITAL FOR SICK CHILDREN (CA) 2013-07-18 — — US disclosed
EP-1725245-B1 MANGANESE AND IRON BASED COMPOUNDS FOR ELASTOGENESIS AND CONNECTIVE TISSUE TREATMENT HUMAN MATRIX SCIENCES LLC (US) 2012-01-25 — — EP disclosed
US-20100247454-A1 COMPOSITIONS FOR ELASTOGENESIS AND CONNECTIVE TISSUE TREATMENT NULASTIN, INC. 2010-09-30 — — US disclosed
US-7666829-B2 contains manganese chloride, manganese sulfate or manganese nitrate and ferric ammonium citrate or ferric chloride, for treating skin disorders; stimulating production of insoluble elastin, or deposition of collagen, fibroblasts; improve the appearance of scar; wrinkle resistance HUMAN MATRIX SCIENCES, LLC (US) 2010-02-23 — — US disclosed
WO-2009036573-A1 APPARATUS AND METHOD FOR MONITORING CELL BEHAVIOUR INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) 2009-03-26 — — WO disclosed
EP-1725245-A2 MANGANESE AND IRON BASED COMPOUNDS FOR ELASTOGENESIS AND CONNECTIVE TISSUE TREATMENT Human Matrix Sciences, LLC (US) 2006-11-29 — — EP disclosed
US-20050208150-A1 Compositions for elastrogenesis and connective tissue treatment NULASTIN, INC. 2005-09-22 — — US disclosed
WO-2005082386-A2 MANGANESE AND IRON BASED COMPOUNDS FOR ELASTOGENESIS AND CONNECTIVE TISSUE TREATMENT HUMAN MATRIX SCIENCES, LLC (US) 2005-09-09 — — WO disclosed
Send feedback